*仅供医学专业人士阅读参考

吐血整理！

欧洲最负盛名和最具影响力的肿瘤学会议——欧洲肿瘤内科学会（ESMO）年会将在9月如约而至，本次大会时间为9月9日-9月13日（中欧夏令时）。

“医学界肿瘤频道”小编整理了肺癌、乳腺癌领域的LBA（Late-Breaking-Abstract）。其中肺癌领域12项、乳腺癌领域7项！（以下排名不分先后，如有遗漏敬请谅解，欢迎留言补充）

肺癌

1、专场：Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies

Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC): updated results from ADAURA

摘要号：LBA47

巴黎时间：9月11日08:30-08:40

中国时间：9月11日14:30-14:40

2、专场：Proffered Paper session: NSCLC, metastatic

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

摘要号：LBA51

巴黎时间：9月11日14:45-14:55

中国时间：9月11日20:45-20:55

3、专场：Proffered Paper session: NSCLC, metastatic

ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib

摘要号：LBA53

巴黎时间：9月11日15:05-15:15

中国时间：9月11日21:05-21:15

4、专场：Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies

CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)

摘要号：LBA49

巴黎时间：9月11日09:25-09:35

中国时间：9月11日15:25-15:35

5、专场：Proffered Paper session: NSCLC, metastatic

Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

摘要号：LBA51

巴黎时间：9月11日14:55-15:05

中国时间：9月11日20:55-21:05

6、专场：Proffered Paper session: Investigational immunotherapy

A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)

摘要号：LBA37

巴黎时间：9月9日16:00-16:10

中国时间：9月9日21:00-21:10

7、专场：Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies

Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816

摘要号：LBA50

巴黎时间：9月12日15:25-15:30

中国时间：9月12日21:25-21:30

8、专场：Proffered Paper session: NSCLC, metastatic

Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non small cell lung cancer (NSCLC): the EMPOWER-Lung 1 trial

摘要号：LBA54

巴黎时间：9月11日15:35-15:45

中国时间：9月11日21:35-21:45

9、专场：Mini Oral session: NSCLC, metastatic

MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): a Phase 1b/2 trial

摘要号：LBA56

巴黎时间：9月11日10:20-10:25

中国时间：9月11日16:20-16:25

10、专场：Mini Oral session: NSCLC, metastatic

Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)

摘要号：LBA59

巴黎时间：9月11日11:05-11:10

中国时间：9月11日17:05-17:10

11、专场：Mini Oral session: NSCLC, metastatic

Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small-cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: second interim analysis of phase 3 ORIENT-31 study

摘要号：LBA58

巴黎时间：9月11日10:45-10:50

中国时间：9月11日16:45-16:50

12、专场：Mini Oral session: NSCLC, metastatic

Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): an open label, multi-center, randomized, phase 2 study

摘要号：LBA57

巴黎时间：9月11日10:45-10:50

中国时间：9月11日16:45-16:50

乳腺癌

1、专场：Proffered Paper session: Breast cancer, early stage

Nivolumab and ipilimumab in early stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): first results from the BELLINI trial

摘要号：LBA13

巴黎时间：9月10日10:25-10:35

中国时间：9月10日16:25-16:35

2、专场：Proffered Paper session: Breast cancer, metastatic

Dalpiciclib plus letrozole or anastrozole as 1st-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): a phase 3 trial

摘要号：LBA16

巴黎时间：9月9日16:10-16:20

中国时间：9月9日20:10-20:20

3、专场：Proffered Paper session: Breast cancer, metastatic

Primary endpoint results of SYNERGY, a randomized phase 2 trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC).

摘要号：LBA17

巴黎时间：9月9日16:20-16:30

中国时间：9月9日22:20-22:30

4、专场：Mini Oral session: Breast cancer, metastatic

Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): a randomized, open-label, phase 2 trial

摘要号：LBA18

巴黎时间：9月10日14:45-14:50

中国时间：9月10日20:45-20:50

5、专场：Mini Oral session: Breast cancer, metastatic

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): a randomized phase 3 trial

摘要号：LBA19

巴黎时间：9月10日14:45-14:50

中国时间：9月10日20:45-20:50

6、专场：Mini Oral session: Breast cancer, metastatic

Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors

摘要号：LBA20

巴黎时间：9月10日15:05-15:10

中国时间：9月10日21:05-21:10

7、专场：Proffered Paper session: Breast cancer, metastatic

Overall survival (OS) results from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

摘要号：LBA76

巴黎时间：9月9日16:20-16:30

中国时间：9月9日22:20-22:30

本文首发：医学界肿瘤频道

本文作者：乌龙茶

责任编辑：Sweet